COMP <GO>
BIIB vs MRNA // PIOTROSKI F-SCORE QUALITY
Biogen Inc. (NASDAQ) VS. Moderna Inc. (NASDAQ) • 15-METRIC TALLY: BIIB 9
— MRNA 2
▲ PIOTROSKI F-SCORE QUALITY LEADER: BIIB
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
piotroski-score
7/9
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. MRNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | MRNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 55.30% | +20.40 | BIIB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | -34.10% | +40.50 | BIIB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | -2.32% | +7.88 | BIIB | /fcf-yield <GO> |
| Operating Margin | 15.90% | -60.00% | +75.90 | BIIB | /operating-margins <GO> |
| Net Profit Margin | 13.10% | -60.00% | +73.10 | BIIB | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | -39.90% | +42.10 | BIIB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 15.07 | -11.37 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 5/9 | +2.00 | BIIB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.8 | 57.7 | +4.10 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.10 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 32.0x | -5.50 | BIIB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.90B | $88.93B | -$52.03B | MRNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | MRNA REV | BIIB GROSS % | MRNA GROSS % | BIIB FCF | MRNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $1.94B | 75.7% | 55.3% | $2.05B | -$2.06B |
| FY 2024 | $9.68B | $3.24B | 76.1% | 54.8% | $2.72B | -$4.05B |
| FY 2023 | $9.84B | $6.85B | — | — | $1.10B | -$3.43B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
MRNA // BETA 1.10